Skip to main content

Table 2 Correlations among QLQ-CIPN20, PRO-CTCAE numbness and tingling items, TNSc©, and worst CIPN pain intensity scores

From: Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors

Measure PRO-CTCAE numbness and tingling items 0–10 worst CIPN pain intensity QLQ-CIPN20 TNSc©
Severity Interference Sensory Motor
PRO-CTCAE Severity 1 0.59 0.65 0.72 0.50 0.48
PRO-CTCAE Interference   1 0.55 0.53 0.58 0.30
0–10 Worst CIPN Pain Intensity    1 0.56 0.40  0.27
QLQ-CIPN20 Sensory     1  0.56  0.48
QLQ-CIPN20 Motor       1  0.40
TNSc©        1
  1. Table describes correlations among the PRO-CTCAE Numbness and Tingling Severity and Interference Items, QLQ-CIPN20, 0–10 worst CIPN pain intensity NRS (n = 138), and TNSc© (n = 118) at T3
  2. CIPN-Chemotherapy-Induced Peripheral Neuropathy, PRO-CTCAE™—Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events, QLQ-CIPN20-Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale, TNSc©—Total Neuropathy Score-Clinical Version